研讨会1：临床试验之最适化

9月22日：会前短期课程
生物标记分析试样之开发与检证 

第3回
Adaptive Clinical Trial Designs
Managing Complexity for Successful Implementation
September 22-24

第3回
Clinical Biomarkers
Optimizing Drug Development
September 24-25

研讨会2：个性化医疗之实现

9月22日会前短期课程
实现个性化医疗之次世代技术

第1回
Personalized Medicine
Delivering on the Promise
September 22-24

第1回
Targeted Therapy 
Towards Individualized Cancer Treatment
September 24-25

研讨会3：癌症治疗之进歩

9月22日会前短期课程
新癌症生物标记

第2回
Translational Cancer Medicine 
Optimizing Oncology Drug and Diagnostic Development
September 22-24

第1回
Circulating Tumor Cells 
Shaping the Future of Cancer Care
September 24-25

研讨会4：生物标记开发中各数据库之结合

9月22日会前短期课程
生物标记之检证 

第3回
Biomarker Data Analysis 
Integrating Biomarker Data and Establishing Biological and Clinical Relevance
September 22-24

第7回
Protein Biomarkers 
Overcoming Translational Challenges
September 24-25

 J. Carl Barrett
VP and Global Head
Oncology Translational Medicine, Novartis

 Nicholas C. Dracopoli
VP, Biomarkers, Centocor R&D
Johnson & Johnson

 Giora Feuerstein
AVP, Head, Discovery Translational Medicine
Wyeth Research

  Stephen H. Friend
President
Sage

  Mark J. Ratain
Chairman, Clinical Pharmacology and
Pharmacogenomics
Cancer Research Center, Univ. Chicago

  Allen D. Roses
Director, Deane Drug Discovery Institute
Duke Univ. School of Medicine

 Douglas C. Throckmorton
Deputy Director
Center for Drug Evaluation and Research, U.S. Food and Drug Administration

  Frank L. Douglas
Senior Fellow, Ewing Marion Kauffman Foundation;
and Senior Partner, PureTech Ventures